Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.14.5741

Expression and Underlying Roles of IGFBP-3 in Paclitaxel-Treated Gastric Cancer Sgc-7901 Cells  

Huang, Gang (Gansu Provincial Hospital)
Dang, Zhong-Feng (The Tumor Hospital of Gansu Province)
Dang, Ya-Mei (Gansu Provincial Hospital)
Cai, Wei (Gansu Provincial Hospital)
Li, Yuan (Gansu Provincial Hospital)
Chen, Yi-Rong (Gansu Provincial Hospital)
Xie, Xiao-Dong (School of Basic Medical Sciences, Lanzhou University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.14, 2014 , pp. 5741-5745 More about this Journal
Abstract
Purpose: To study the expression of insulin-like growth factor binding proteins (IGFBPs) in paclitaxel-treated gastric cancer SGC-7901 cells, and to further investigate underlying mechanisms. Materials and Methods: Real time PCR and Western blot assays were applied to detect the mRNA and protein expression of IGFBP-2, -3 and -5 after paclitaxel (10 nM) treatment of SGC-7901 cells. In addition IGFBP-3 expression was silenced by RNA interference to determine effects. Cell viability was determined by MTT assay. Cell cycling and apoptosis were assessed by flow cytometry. Results: Compared to the control group, only IGFBP-3 expression was elevated significantly after paclitaxel (10 nM) treatment (p<0.05). Paclitaxel treatment caused cell cycle arrest and apoptosis via downregulating Bcl-2 expression. However, the effect could be abrogated by IGFBP-3 silencing. Conclusions: IGFBP-3 exhibits anti-apoptotic effects on paclitaxel-treated SGC-7901 cells via elevating Bcl-2 expression.
Keywords
IGFBPs; paclitaxel; gastric cancer; apoptosis;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Adams JM, S Cory (1998). The Bcl-2 protein family: arbiters of cell survival. Science, 281, 1322-6.   DOI   ScienceOn
2 Alami N, V Page, Q Yu, et al (2008). Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res, 18, 487-96.   DOI
3 Biernacka KM, CC Uzoh, L Zeng, et al (2013). Hyperglycaemiainduced chemoresistance of prostate cancer cells due to IGFBP2. Endocr Relat Cancer, 20, 741-51.   DOI
4 Cortes-Sempere M, MP de Miguel, O Pernia, et al (2013). IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/ Akt pathway in non-small cell lung cancer. Oncogene, 32, 1274-83.   DOI
5 Dang YM, Huang G, Chen YR, et al (2014). Sulforaphane inhibits the proliferation of the BIU87 bladder cancer cell line via IGFBP-3 elevation. Asian Pac J Cancer Prev. 15, 1517-20.   과학기술학회마을   DOI
6 Duggan C, CY Wang, ML Neuhouser, et al (2013). Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. Int J Cancer, 132, 1191-200.   DOI
7 Eichhorn JM, SE Alford, N Sakurikar, et al (2014). Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival. Exp Cell Res, 322, 415-24.   DOI
8 Foulstone EJ, L Zeng, CM Perks, et al (2013). Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. Endocrinology, 154, 1780-93.   DOI
9 Holdaway IM, BH Mason, AE Lethaby, et al (2003). Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg, 73, 905-8.   DOI   ScienceOn
10 Liang PI, YH Wang, TF Wu, et al (2013). IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. J Clin Pathol, 66, 573-82.   DOI
11 Kiyoshima T, H Yoshida, H Wada, et al (2013). Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression. PLoS One, 8, 80998.   DOI
12 Koyama S, LJ Cobb, HH Mehta, et al (2010). Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res, 20, 55-62.   DOI
13 Kalluri HS, RJ Dempsey (2011). IGFBP-3 inhibits the proliferation of neural progenitor cells. Neurochem Res, 36, 406-11.   DOI
14 Williams AC, H Smartt, HZ AM, et al (2007). Insulin-like growth factor binding protein 3 (IGFBP-3) potentiates TRAIL-induced apoptosis of human colorectal carcinoma cells through inhibition of NF-kappaB. Cell Death Differ, 14, 137-45.   DOI   ScienceOn
15 Peters I, I Tossidou, J Achenbach, et al (2006). IGF-binding protein-3 modulates TGF-beta/BMP-signaling in glomerular podocytes. J Am Soc Nephrol, 17, 1644-56.   DOI
16 Kang WK, I Lee, U Ko, et al (2005). Differential effects of RhoA signaling on anticancer agent-induced cell death. Oncol Rep, 13, 299-304.
17 Soubry A, D Il'yasova, R Sedjo, et al (2012). Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps. Int J Cancer, 131, 512-7.   DOI
18 Sunderic M, B Dukanovic, V Malenkovic, et al (2014). Molecular forms of the insulin-like growth factor-binding protein-2 in patients with colorectal cancer. Exp Mol Pathol, 96, 48-53.   DOI
19 Vallon M, C Seidl, B Blechert, et al (2012). Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest. Eur J Nucl Med Mol Imaging, 39, 1886-97.   DOI
20 Wang X, JJ Beitler, H Wang, et al (2014). Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis. PLoS One, 9, 86369.   DOI
21 Zhang GJ, Z Zhang (2013). Effect of Bcl-2 on apoptosis and transcription factor NF-kappaB activation induced by adriamycin in bladder carcinoma BIU87 cells. Asian Pac J Cancer Prev, 14, 2387-91.   과학기술학회마을   DOI   ScienceOn
22 Zeng L, C Jarrett, K Brown, et al (2013). Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the antitumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells. Exp Cell Res, 319, 2282-95.   DOI
23 Hossein G, Keshavarz M, Ahmadi S, et al (2012). Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev, 14, 7561-8.   과학기술학회마을   DOI   ScienceOn